Multicenter Phase II Study of Reduced-Dose CHOP Chemotherapy Combined with Rituximab for Elderly Patients with Diffuse Large B-Cell Lymphoma

To evaluate the efficacy and toxicity of reduced-dose (RD) rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone (RCHOP) chemotherapy for elderly patients with diffuse large B-cell lymphoma (DLBCL), 53 patients aged ≥ 65 years in South Korea, were enrolled in this study. RD-RCHOP chemotherapy showed comparable survival benefits, compared to those of the previous reduced dose of CHOP-like chemotherapy plus rituximab.

Source: Clinical Lymphoma, Myeloma and Leukemia - November 12, 2018 Category: Hematology Authors: Sungwoo Park, Jae-Cheol Jo, Young Rok Do, Deok-Hwan Yang, Sung-Nam Lim, Won-Sik Lee, Won Seog Kim, Ho Sup Lee, Dae-Sik Hong, Hyo Jung Kim, Ho-Jin Shin Source Type: research